7,700 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Acquired by Bellevue Group AG

Bellevue Group AG bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,700 shares of the company’s stock, valued at approximately $128,000.

Other institutional investors also recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new stake in shares of NewAmsterdam Pharma in the second quarter valued at $38,000. Rosalind Advisors Inc. purchased a new stake in NewAmsterdam Pharma in the 2nd quarter valued at about $194,000. Wolverine Asset Management LLC grew its holdings in NewAmsterdam Pharma by 117.7% in the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock valued at $298,000 after buying an additional 8,394 shares during the period. Sei Investments Co. increased its stake in shares of NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after acquiring an additional 8,087 shares during the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth about $700,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84. Following the completion of the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 86,803 shares of company stock valued at $1,755,307. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $19.85 on Monday. The firm has a fifty day moving average of $19.55 and a 200-day moving average of $18.57. NewAmsterdam Pharma has a 52-week low of $8.90 and a 52-week high of $26.35.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NAMS shares. Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.80.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.